Actress Mallika Sukumaran highlights Importance of Early Diagnosis in Fight Against Breast Cancer

Thiruvananthapuram: Renowned actor Mallika Sukumaran emphasized the critical importance of early detection in the fight against breast cancer, urging women to overcome their reluctance towards regular medical check-ups.

Speaking at the release of the book ‘Breast Cancer: Things to Know’, authored by Dr Chandramohan K (Senior Surgical Oncologist), Dr Boben Thomas (Senior Medical Oncologist), Dr. Ajai Sasidhar (Surgical Oncologist), and Dr. Teena Nelson (Radiation Oncologist), at the newly operational SP Medifort Hospital, she pointed out that Kerala ranks highest in the number of breast cancer patients in India, news agency UNI reported.

The disease, which is the most prevalent form of cancer among women, can be successfully treated if detected early, she noted, urging both government and private institutions to enhance awareness initiatives and create a comprehensive database on breast cancer cases.

Also Read:174-bed cancer hospital coming up at cost of Rs 213 crores in Bandra West

Expressing concern over the increasing number of patients, SP Medifort Chairman and Managing Director Dr SP Asokan assured that the hospital would intensify efforts to raise awareness about breast cancer, underscoring the need for collective action to tackle the issue.

Joint Chairman & Managing Director, SP Subramonian also addressed the gathering, stressing the importance of early diagnosis.

“We must not assume that a cancer diagnosis is a point of no return. The will to detect the disease early and fight it is crucial,” he said, adding that SP Medifort has one of the best-equipped oncology departments in Kerala, offering advanced treatment facilities and expert care.

SP Medifort Executive Directors Dr. S Aathithya and Advaith A Bala spoke at this public event which was attended by a large gathering of medical students, doctors, patients and cancer survivors.

In a bid to promote early detection,  SP Medifort Hospital has initiated a free breast cancer screening camp since 1st October, with individuals and organizations encouraged to register for a “free oncologist consultation and also avail 20 percent discount on investigations and advanced cancer health checkups, for October” said Tanjai Kapoor, Chief Marketing Officer, SP Medifort.

The hospital’s cancer survivor association, Cancer Warriors, continues to actively campaign and raise awareness about the disease, providing support and information to patients and their families, he said.

Also Read:CM Sukhu inaugurates tertiary cancer hospital building built at cost of Rs 13.50 crore

Powered by WPeMatico

ESIC Hospital Noida Recruitment: SR, Specialists, Super Specialists Post: Apply Now

Noida: The Employees State Insurance Corporation (ESIC Model Hospital, Noida) has released vacancies for Senior Resident, Specialists, and Super Specialists posts on a Contract Basis in various departments.

ESIC is a statutory body constituted under an Act of Parliament (ESI Act, 1948) and works under the administrative control of the Ministry of Labour and Employment, Government of India.

Vacancy Details:

Total No of Vacancies: 21

Super Specialist:- 02

The vacancies are in the Department of Gastroenterology and Neurology.

Specialist:- 03

The vacancies are in the Anesthesia, Pathology, and Gynecology.

Senior Resident:- 16

The vacancies are in the Anesthesia, Orthopedics, Surgery, ICU, Pediatrics, NICU, Chest, Radiology, Gynecology, Casualty, and ENT.

Date of Walk-in-Interview: 23rd October 2024.

Venue of Interview: Conference Room, Ground Floor, ESIC Model Hospital, Noida on 09:30 AM onwards.

For more details about Qualifications, Age, Pay Allowance, and much more, click on the given link:
https://medicaljob.in/jobs.php?post_type=&job_tags=esic+noida&location=&job_sector=all

Note for Candidates:-

Interested candidates may appear for the Walk in interview as per given schedule along with their original documents & Xerox copies in support of their Date of Birth, Proof of Educational Qualification, Experience Certificates, Caste Certificates.

Candidates reporting after 11:00 am will not be allowed to appear in the walk in interview. Documents required:-

1. Matriculation certificate for Age proof

2. MBBS Certificate/Proof of Educational Qualification (with mark sheets)

3. Two Photographs (PP Size).

4. Aadhar Card

5. PAN Card

6. Caste Certificate for SC/ST/OBC candidates. OBC candidates are required to submit latest OBC Certificate as per Central Govt. Performa, not more than one year old from the date of Interview.

7. PG Degree/Diploma Certificate.

8. DMC/UPMCI Registration Certificate with MD/MS/DNB qualification.

9. No Objection Certificate from present employer, if applicable.

10. Experience Certificates, if applicable.

11. Income and Asset certificate from issuing Authority as per DOPT letter no. 36039/1/2019-Estt.(Res) dated 31s January, 2019 must be submitted for the reservation for EWS Category.

12. EWS candidates are required to submit latest EWS Certificate as per Central Govt. Performa, not more than one year old from the date of Interview.

Note: – The number of vacancies may increase/decrease on the basis of joining of Regular Specialists/Super specialists/GDMOs.

Also Read:Walk In Interview For SR Post At Guru Nanak Eye Centre, Delhi: Check Details Here

Powered by WPeMatico

India’s Bioeconomy surges to USD 150 billion, but innovation gaps remain, says BIRAC MD

New Delhi: India’s biotechnology sector is witnessing remarkable growth, with the country’s bioeconomy now valued at USD 150 billion but there is still significant untapped potential in innovation and product development, which could further elevate India’s global standing in the sector, Dr Jitendra Kumar, Managing Director of the government’s Biotechnology Industry Research Assistance Council (BIRAC), said.
BIRAC is a not-for-profit public sector enterprise set up by the Department of Biotechnology (DBT) under the government that supports and promotes innovation, entrepreneurship, and research in the sector.
In an interview with PTI, Kumar highlighted India’s significant contributions to global healthcare, with 40 per cent of the world’s generic medicines being supplied by Indian companies.
“We have enormous potential and capability, but when it comes to the value of our bioeconomy, we are ranked 14th globally. This is because much of the value stems from patented, innovative products’ — an area where India still needs to improve,” Kumar said.
“So that emphasis effort from the government and BIRAC side is to actually promote that which is why we will now be promoting innovations… that is why the biotech industry is concentrating on promoting new innovations and promoting and nurturing them,” he said.
To address this gap, BIRAC is emphasising innovation and nurturing startups through various programmes designed to convert academic research into marketable products.
“Our goal is to promote academic conversion into enterprise. Through initiatives like the Promoting Academic Conversion to Enterprise (PACE), we’re helping scientists move their research out of labs and into the market,” he said.
Since its formation in 2012, BIRAC has played a critical role in creating a biotech innovation ecosystem, he said.
Kumar shared that the number of biotech startups in India has grown exponentially from about 300 to over 8,000, with significant government support driving this expansion. Additionally, the bioeconomy has surged from USD 35 billion to USD 150 billion in just a decade.
A key achievement of BIRAC, Kumar said, has been the creation of bio-incubation centres across India, providing crucial infrastructure for startups to develop proof-of-concept products.
“Startups often face challenges in finding laboratory space. Our bio-incubation centres offer ‘plug and play’ laboratories, which have made it easier for startups to carry out their research and development,” he added.
However, despite these advancements, India still lags in research and development (R&D) spending, investing just 0.8 per cent of its GDP in R&D compared to developed nations like the US and China, which spend over 2 per cent.
Kumar stressed that increasing private-sector investment in R&D is essential for India to realise its potential as a global biotech leader.
“We are working on programmes that encourage industries to invest in R&D alongside government funding. For instance, our Biotech Industry Partnership Program requires co-funding from industry players,” he said.
Kumar also acknowledged regulatory challenges faced by biotech startups but emphasised that BIRAC is working to alleviate these issues through regulatory advocacy and policy initiatives.
“Many startups face difficulties due to a lack of understanding of regulatory processes. We have created a Regulatory and Policy Advocacy Cell to guide startups and engage with regulatory bodies to ease these challenges,” he noted.
Kumar said he is optimistic about India’s biotech future.
The government’s commitment to increasing R&D investment through initiatives like the National Research Foundation and its efforts to align regulatory frameworks with global standards will be key drivers of future growth.
“If we continue to support innovation and streamline regulations, India can not only increase its bioeconomy but also emerge as a global biotech innovator,” he said.

Powered by WPeMatico

PM Modi inaugurates R J Sankara Eye Hospital in Varanasi

Varanasi: Prime Minister Narendra Modi inaugurated R J Sankara Eye Hospital in Varanasi on Sunday, which will provide comprehensive consultations and treatments for various eye conditions.

According to the PTI report, run by the Kanchi Math, R J Sankara Eye Hospital will benefit people of 20 districts of eastern Uttar Pradesh as well as those living in the border areas of Bihar, Madhya Pradesh and Chhattisgarh, people associated with the Kanchi Math said.

This is the Kanchi Math’s 14th hospital in the country. The target is to conduct 30,000 free eye surgeries every year, they said.  

Also Read:BHU Head Cardiology threatens fast unto death; Hospital gives in, allocates bed to dept

Modi is on a day-long visit to Varanasi during which he will launch a number of development initiatives, including multiple airport projects across the country worth over Rs 6,100 crore.  

He arrived at Lal Bahadur Shastri Airport here earlier in the day and was welcomed by Governor Anandiben Patel and Uttar Pradesh Chief Minister Yogi Adityanath.

As the prime minister’s motorcade made its way from the airport towards the city, it was showered with petals by people gathered on roads. He was welcomed with drumbeats.

Ahead of the hospital’s inauguration, Modi met the Shankaracharya of the Kanchi Math.

He also visited an exhibition organised here. He was accompanied by Patel and Adityanath.

Also Read:PM Modi to lay stone for 200-bedded National Centre on Ageing at IMS-BHU

Powered by WPeMatico

Semaglutide cuts obesity, improves Heart Failure symptoms in Atrial Fibrillation: JACC

A recent secondary analysis from the pooled data of the STEP-HFpEF
(Heart Failure with Preserved Ejection Fraction) Program and STEP-HFpEF DM
found that once a week’s prescription of Semaglutide 2.4 mg has led to
significant improvements in Heart failure-related symptoms and physical
limitations in individuals with Atrial Fibrillation (AF) at the baseline than
those without AF. Results from this analysis were published in the Journal of
American College of Cardiology. 


AF is frequently observed in individuals with HFpEF and
leads to adverse outcomes in these individuals compared to those with normal
sinus rhythm. Obesity is an important risk factor for the development and
progression of HFpEF and AF. Previous research from the HFpEF and HFpEF DM
trials showed that Semaglutide had better results in those with HF-related
symptoms, physical limitations, exercise function, body weight, and
obesity-related heart failure in obesity-related HFpEF. However, there is
uncertainty on the efficacy of semaglutide in individuals with or without AF.
Hence, researchers conducted a secondary analysis from the pooled data of the
two trials to evaluate the baseline characteristics, and clinical
features, of obesity-related HFpEF individuals with and without a history of
AF. They also determined the efficacy of Semaglutide across various types of
AF. 

Also Read: Binge drinking associated with increased heart rate and atrial tachycardias: EHJ



Individuals with heart failure, left ventricular
ejection fraction ≥45%, body mass index ≥30 kg/m2, and Kansas City
Cardiomyopathy Questionnaire–Clinical Summary Score (KCCQ-CSS) <90
points were randomized 1:1 to receive once-weekly semaglutide 2.4 mg or
matching placebo for 52 weeks. The endpoints investigated based on the
investigator-reported history of AF included the following:


  • Primary – change in KCCQ-CSS and percent change in body
    weight

    Confirmatory

  • Secondary – change in 6-minute walk distance,
    all-cause death, HF events, thresholds of change in KCCQ-CSS, and 6-minute walk
    distance; and C-reactive protein

  • Exploratory endpoint – change in N-terminal pro–B-type
    natriuretic peptide


Based on the presence of AF, the responder analysis examined
the improvements in the KCCQ-CSS score

Also Read: Heart failure, atrial fibrillation & coronary heart disease linked to cognitive impairment, reveals study

Findings:


  • Among 1145 individuals, 45% had a history of AF of different
    types

    Most of them with AF were older, male, with high levels of
    NTproBNP, were among the NYHA functional class III symptoms, and were taking
    more antithrombotics, beta-blockers, and diuretics.

  • A significant improvement in the KCCQ-CSS score (11.5 vs 4.3
    points was seen in the individuals with AF vs without AF

    A significant proportion of individuals with AF taking
    semaglutide reported ≥5-, ≥10-, ≥15-, and ≥20-point improvement in KCCQ-CSS than
    without AF and on placebo.

  • Apart from these a consistent reduction in the CRP,
    NT-proBNP, and body weight was seen despite the AF status with semaglutide.

Thus, the study concluded that semaglutide was effective in
improving HF-related symptoms and obesity-related heart failure with pronounced
improvements in individuals with AF. Semaglutide proves to be a potential drug
for improving heart failure symptoms and obesity in individuals with AF.          

Further reading: Verma S, Butler J, Borlaug BA, et al. Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program. J Am Coll Cardiol. 2024;84(17):1603-1614. doi:10.1016/j.jacc.2024.08.023

Powered by WPeMatico

Ultra-Short-Term Heart Rate Fluctuations Key Predictors of Sudden Cardiac Death, suggests study

Finland: Recent research has revealed that ultra-short-term fluctuations in heart rate can serve as a significant predictor of sudden cardiac death (SCD), offering new hope in identifying at-risk individuals. The study, which focuses on a specific heart rate measurement known as DFA2 α1, was conducted to assess its effectiveness in predicting SCD, particularly among patients at rest.

“Ultra-short-term DFA2 α1, when assessed at rest, is a strong and independent predictor of SCD. Additionally, the relationship between DFA2 α1 and SCD is influenced by levels of physical exertion,” the researchers wrote in JACC: Clinical Electrophysiology.

Sudden cardiac death remains a leading cause of mortality worldwide, often occurring without warning, making early detection critical. Traditional measures of heart rate variability have demonstrated only weak links to sudden cardiac death. In contrast, detrended fluctuation analysis (DFA), enhanced by new methodological advancements for assessing the short-term scaling exponent, offers a potentially more effective approach than standard HRV methods.

Against the above background, Jussi A. Hernesniemi, Heart Hospital, Tampere University Hospital, Tampere, Finland, and colleagues investigated the relationship between DFA and sudden cardiac death.

For this purpose, the researchers examined the predictive capability of ultra-short-term heart rate fluctuations—specifically, 1-minute electrocardiogram samples—using detrended fluctuation analysis (DFA) both at rest and during various levels of physical exertion. The study involved 2,794 participants from the prospective FINCAVAS (Finnish Cardiovascular Study) who underwent clinical exercise testing.

The primary variable of interest was the novel DFA measure, the short-scale scaling exponent computed with second-order detrending (DFA2 α1).SCDs were identified according to the criteria set by the American Heart Association and the European Society of Cardiology, utilizing death certificates that included detailed accounts of the incidents.

The study led to the following findings:

  • During a median follow-up of 8.3 years (ranging from 6.4 to 10.5 years), 83 cases of sudden cardiac death (SCD) were recorded.
  • The resting measurement of DFA2 α1 showed a strong link to the risk of SCD, with lower values associated with a 2.4-fold increase in risk (ranging from 2.0 to 3.0), which was statistically significant. This relationship remained strong even after accounting for other key risk factors such as age, existing cardiovascular conditions, cardiorespiratory fitness, heart rate changes, and left ventricular ejection fraction.
  • Traditional HRV measurements, whether taken during exercise or at rest, showed weaker and statistically insignificant associations with SCD once these other risk factors were considered.

The findings from the prospective study of patients undergoing clinical exercise testing indicate that a new approach to measuring heart rate variability—derived from just a 1-minute ECG signal—is a highly reliable predictor of sudden cardiac death, regardless of cardiorespiratory fitness, left ventricular ejection fraction, or other significant risk factors for SCD.

Reference:

Hernesniemi, J. A., Pukkila, T., Molkkari, M., Nikus, K., Lyytikäinen, L., Lehtimäki, T., Viik, J., Kähönen, M., & Räsänen, E. (2024). Prediction of Sudden Cardiac Death With Ultra-Short-Term Heart Rate Fluctuations. JACC: Clinical Electrophysiology, 10(9), 2010-2020. https://doi.org/10.1016/j.jacep.2024.04.018

Powered by WPeMatico

How to Improve Results in Diabetic Foot Care?

India: As diabetes rates rise globally, diabetic foot care has become a vital focus in healthcare. A recent review published in Diabetes Research and Clinical Practice outlines significant advancements and best practices in managing diabetic foot complications, including foot ulcers, neuropathy, vascular disease, and amputation risks.

A central theme of the review is the necessity of a multidisciplinary approach. The collaboration of diabetologists, podiatrists, vascular surgeons, and wound care specialists is crucial for improving patient outcomes. This teamwork enables healthcare providers to deliver comprehensive care that addresses the multifaceted complications associated with diabetes.

Innovative wound management techniques are among the key advancements highlighted. The review emphasizes the effectiveness of advanced dressings and bioengineered skin substitutes, which enhance healing and lower infection risks. Additionally, offloading devices, such as total contact casts and specialized footwear, are essential in preventing pressure-related injuries, particularly for patients with existing ulcers.

Early detection and intervention are also critical components of diabetic foot care. The review stresses the importance of conducting vascular evaluations as a baseline investigation. Assessments like the Ankle-Brachial Index (ABI) and Toe-Brachial Index (TBI), carried out by trained podiatrists, can help identify peripheral artery disease (PAD) early. Techniques such as arterial color Doppler and duplex scans are valuable for diagnosing vascular issues that may lead to foot complications.

Technological innovations further enhance diabetic foot care. Telemedicine platforms enable remote consultations and continuous monitoring, while wearable devices allow for real-time tracking of foot health, facilitating timely interventions. Mobile applications are vital educational resources, helping patients adhere to foot care routines.

Despite these advancements, significant disparities in access to care and treatment outcomes persist globally. Socioeconomic factors, healthcare infrastructure, and the availability of specialized services contribute to these inequalities, resulting in varied management and outcomes for diabetic foot complications.

Addressing these challenges requires concerted efforts from policymakers, healthcare providers, and community organizations to ensure equitable healthcare access for all individuals with diabetes. By synthesizing the latest advancements and best practices, this review aims to support ongoing efforts to improve the quality of life for those affected by diabetic foot conditions worldwide.

“This comprehensive review serves as an essential resource for healthcare professionals, policymakers, and researchers dedicated to advancing diabetic foot care,” concluded authors Smita Kumbhar and Manish Bhatia, from India. They emphasize the need for continued research and policy initiatives to enhance global patient outcomes and advocate for a collaborative, patient-centered approach in managing this critical aspect of diabetes care.

Reference:

Kumbhar, S., & Bhatia, M. (2024). Advancements and best practices in diabetic foot Care: A comprehensive review of global progress. Diabetes Research and Clinical Practice, 217, 111845. https://doi.org/10.1016/j.diabres.2024.111845

Powered by WPeMatico

Regular Seafood Consumption Linked to Lower Risk of Persistent Tinnitus in Women: Study

Researchers established that seafood consumption, even at regular rates, particularly tuna, light-meat fish, and shellfish, is highly related to a lower risk of developing persistent tinnitus among women. A recent study was published in The American Journal of Clinical Nutrition conducted by Sharon G. and colleagues. The study probed into the potential association between seafood consumption and supplementation with fish oil regarding the risk for the development of persistent tinnitus, a common debilitating illness characterized by ringing or noise in the ears on a daily basis.

Tinnitus is a condition for which very few standard treatments exist, and it may indeed be a terribly life-disabling disorder. Since seafood intake has been associated with a lower risk of hearing loss, the authors of this study aimed to explore whether a similar association between seafood consumption and the development of persistent tinnitus might exist. The purpose of this study was to evaluate the independent effect of total seafood intake, specific types of fish, shellfish, and use of fish oil supplements on the risk of developing persistent tinnitus in women.

This cohort study followed 73,482 women who were enrolled in the Nurses’ Health Study II from 1991 through 2021. Diet data were collected by using a validated food frequency questionnaire, which is given every 4 years. The questionnaire examined the consumption frequency of seafood and, specifically, the consumption of certain types of fish (tuna, light-meat fish, dark-meat fish), shellfish, and fish oil supplements. Tinnitus that persisted was defined when tinnitus occurred every day. Multivariable-adjusted associations between seafood intake, fish oil supplements, and the risk of tinnitus were measured using Cox proportional hazards regression, with adjustments for any confounding factors by age, diet, and lifestyle.

Summary of Key Finding

  • During the follow-up periods of 1,998,421 person-years, 9,362 new-onset persistent tinnitus cases were reported.

  • The study established a positive association between increased amounts of seafood and reduced risks of the development of tinnitus.

  • Compared to those who had no seafood consumption, were 0.87 (95% CI, 0.78-0.95) per serving per week.

  • Pooled multivariate HR: 0.77 (95% CI, 0.68-0.86) for 2-4 servings per week, and 0.79 (95% CI, 0.64-0.96) for 5+ servings per week (p <0.0001).

When seafood types were examined separately, regular consumption of tuna fish, light-meat fish and shellfish was inversely related to the risk of tinnitus:

  • Tuna fish: MVHR of 0.84 (95% CI, 0.78-0.90) for 1 or more servings per week (p <0.0001),

  • Light-meat fish: MVHR of 0.91 (95% CI, 0.83-0.99) for 1 or more servings per week (p = 0.04),

  • Shellfish: MVHR of 0.82 (95% CI, 0.72-0.93) for 1 or more servings per week (p <0.0001).

  • Darker-meat fish intake was associated with higher risks of tinnitus, with an MVHR of 1.09 (95% CI, 0.99-1.21; p = 0.04). Moreover, fish oil supplementation was associated with a higher risk of chronic tinnitus, with an MVHR of 1.12 (95% CI, 1.06-1.19).

These results pointed out the relevance of dietary patterns in preventing tinnitus and suggested that increasing seafood in the diet may also be helpful in lowering the risk for this debilitating condition. Therefore, the mechanisms underlying the phenomenon in question require further research for full understanding. These can then serve as guidelines for recommendations of safe consumption of seafood and supplement intake to prevent tinnitus.

Reference:

Curhan, S. G., Zeleznik, O. A., & Curhan, G. C. (2024). Longitudinal study of seafood and fish oil supplement intake and risk of persistent tinnitus. The American Journal of Clinical Nutrition. https://doi.org/10.1016/j.ajcnut.2024.09.028

Powered by WPeMatico

Infants who received only breast milk at birth during hospitalization have lower asthma rates: Study

Infants who were exclusively fed breast milk during their hospitalization at birth were 22% less likely to develop asthma in early childhood, according to research presented during the American Academy of Pediatrics 2024 National Conference & Exhibition in Orlando.

The abstract, “Association Between Hospital Feeding Patterns and Childhood Asthma,” found lower rates of asthma in the infants born at the Cincinnati Children’s Hospital Medical Center who were exclusively fed breast milk even after adjusting for maternal race, insurance, infant sex, and length of hospital stay. Researchers will present their findings during the conference at the Orange County Convention Center from Sept. 27-Oct.

“Although the birth hospitalization lasts only a few days, it sets a critical foundation for establishing breastfeeding, which can influence health outcomes like childhood asthma,” said Laura Placke Ward MD, IBCLC, FAAP, a study author and co-director for the Center for Breastfeeding Medicine at Cincinnati Children’s Hospital Medical Center.

“Our study underscores the importance of hospital practices in supporting exclusive breastfeeding, as these early experiences may impact long-term health,” she said.

While longer duration and exclusive breastfeeding are known to reduce asthma risk, the effect of breastfeeding during the birth hospitalization is less understood, the authors note.

Of the 9,649 children included in the study, 81% received some breast milk and 31% exclusively received breast milk during the birth hospitalization. Five percent had a diagnosis of asthma. Infants who received only breast milk had a lower rate of asthma diagnosis compared to those who did not receive any breast milk or did not receive breast milk exclusively after adjusting for sex, race, and insurance status. Additionally, infants whose first feeding was breast milk also had a lower rate of asthma compared to those whose first feeding was not breast milk.

“This finding highlights the need for greater emphasis on supporting and promoting exclusive breastfeeding during the early days of life,” Dr. Ward said. “By focusing on these crucial first days, we may impact children’s health and potentially reduce the risk of chronic conditions like asthma.”

Reference:

Asthma rates lower in children who received only breast milk at birth hospital, American Academy of Pediatrics, Meeting: American Academy of Pediatrics 2024 National Conference & Exhibition.

Powered by WPeMatico

Conversion from sleeve gastrectomy to Ring augmented Roux-en-Y gastric bypass safe and effective for weight loss: Study

Conversion from sleeve gastrectomy to Ring augmented Roux-en-Y gastric bypass safe and effective for weight loss suggest a study published in the BMC Surgery.

Weight recurrence, suboptimal clinical response and functional disorder (such as reflux) after a Sleeve Gastrectomy (SG) are problems that may require conversional surgery. For reflux, conversion to Roux-en-Y Gastric Bypass (RYGB) is considered effective. Regarding treatment for suboptimal clinical response, the technique of choice remains a subject of debate. This study aims to evaluate the safety and effectiveness of conversion from SG to Ring-augmented RYGB ( RaRYGB). All laparoscopic SG to RaRYGB conversions performed between January 2016 and January 2022 were included. Primary outcome was percentage total weight loss (%TWL) after 1-year follow-up.

Secondary outcomes consisted of cumulative %TWL, complications (with a focus on ring-related complications), and resolution of medical-associated problems.Results: They included 50 patients of whom 44 were female. Mean pre-conversion BMI was 37.6 kg/m2. All patients have reached the 1-year follow-up point, however 10 were lost to follow-up. After 1-year mean TWL was 17.8% while mean cumulative TWL, calculated from primary SG, was 32%. A total of 10 complications occurred in 8 patients within 30 days, 6 of which were ≤ CD3a and 4 ≥ CD3b.

One MiniMizer was removed for complaints of severe dysphagia. Of the 35 medical-associated problems present at screening 5 remained unchanged(14.2%), 15 improved(42.9%) and 15 achieved remission(42.9%). The series of 50 patients undergoing conversion from SG to RaRYGB is adequate and successful regarding additional weight loss 1 year after conversion, cumulative weight loss, complication rate and achievement of improvement or remission of medical-associated problems.

Reference:

van Dam, K.A.M., de Witte, E., Broos, P.P.H.L. et al. Short-term safety and effectiveness of conversion from sleeve gastrectomy to Ring augmented Roux-en-Y gastric bypass. BMC Surg 24, 266 (2024). https://doi.org/10.1186/s12893-024-02552-7

Powered by WPeMatico